Brief: Oncternal Therapeutics To Present Updated Interim Phase 1/2 Data For Zilovertamab In Combination With Ibrutinib
03/11/2022 14:58
Nov 3 (Reuters) - Oncternal Therapeutics Inc ONCT.O :
* ONCTERNAL THERAPEUTICS TO PRESENT UPDATED INTERIM PHASE
1/2 DATA
FOR ZILOVERTAMAB IN COMBINATION WITH IBRUTINIB IN AN ORAL
SESSION AT ASH 2022
Source text for Eikon: ID:nGNX3hMJvC
Further company coverage: ONCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncternal Therapeutics
See all newsOncternal Therapeutics Inc expected to post a loss of $3.19 a share - Earnings Preview
Brief: Oncternal Therapeutics Workforce Reduction Of About 10 Employees
U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery
Oncternal hits record low on plans to scrap studies, explore strategic alternatives;